#OCGN Ocugen and Roots Pharmaceutical Complete License Agreement for OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the M…

https://www.stocktitan.net/news/OCGN/ocugen-and-roots-pharmaceutical-complete-license-agreement-for-qm1lia15vmlu.html?utm_source=stocktitan-bluesky&utm_medium=social

🔴 $OCGN — Musunuri Shankar, Chief Executive Officer
SOLD: 468,727 shares @ $0.95
Total: $445K
Filed Oct 8, 2026 · 8:00pm ET
📈 History & trend → https://www.formdelta.com/ticker/OCGN

#InsiderTrading #OCGN #StockMarket

#OCGN Ocugen Appoints Industry Executive Jolanda Crombach General Manager of European Affiliate

https://www.stocktitan.net/news/OCGN/ocugen-appoints-industry-executive-jolanda-crombach-general-manager-hzufji29p3u8.html?utm_source=stocktitan-bluesky&utm_medium=social

#OCGN Ocugen to Participate in Upcoming October Investor and Industry Conferences

https://www.stocktitan.net/news/OCGN/ocugen-to-participate-in-upcoming-october-investor-and-industry-52v3f46z8r0w.html?utm_source=stocktitan-bluesky&utm_medium=social

📄 $OCGN 10-Q — what changed
MD&A now says: "You should read the "Risk Factors" section included in our 2025 Annual Report and First Quarter 10-Q and "Disclosure Regarding Forward-Looking Statements" section of this Quarterly Report on Form 10-Q for a discussion of important factors that could cause

🔴 $OCGN — Musunuri Shankar, Chief Executive Officer
SOLD: 468,727 shares @ $1.12
Total: $525K
Filed Sep 8, 2026 · 8:00pm ET
📈 History & trend → https://www.formdelta.com/ticker/OCGN

#InsiderTrading #OCGN #StockMarket